<DOC>
	<DOCNO>NCT00766116</DOCNO>
	<brief_summary>This study test experimental combination drug Mylotarg 5-azacitidine hope find treatment may effective Acute Myeloid Leukemia come back treatment .</brief_summary>
	<brief_title>Combination 5-azacitidine Gemtuzumab Ozogamicin Therapy Treatment Relapsed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>In Phase I portion study patient diagnosis AML relapse disease treat assign number dos 5 azacitidine follow Mylotarg administer two time two week In Phase II portion study patient treat dose 5azacitidine determine safe Phase I portion study follow Mylotarg . A sample blood bone marrow obtain prior initiation treatment another sample obtain treatment 5-azacitidine Mylotarg sample test laboratory determine response treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Diagnosis Relapsed AML Eastern Cooperative Oncology Group ( ECOG ) performance status 02 , life expectancy &gt; 3 month â‰¥ 18 year old Previously untreated current AML relapse Adequate organ function Written inform consent Pregnant breastfeed woman Growth factor support platelet white cell number function must administer within past 7 day Currently receive another investigational drug Currently receive anticancer agent Uncontrolled infection HIV positive Received previous therapy either Mylotarg 5azacitidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
</DOC>